Literature DB >> 15945099

Gene regulation profile reveals consistent anticancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor.

Joyce C L Leo1, Suk Mei Wang, Chun Hua Guo, Swee Eng Aw, Yi Zhao, Jin Ming Li, Kam M Hui, Valerie C L Lin.   

Abstract

Absence of estrogen receptor (ER) and progesterone receptor (PR) is the hallmark of most hormone-independent breast cancers. Previous studies demonstrated that reactivation of PR expression in hormone-independent MDA-MB-231 breast cancer cells enabled progesterone to suppress cell growth both in vitro and in vivo. We determined the whole genomic effect of progesterone in PR-transfected MDA-MB-231 cells. We identified 151 progesterone-regulated genes with expression changes > 3-fold after 24 hr treatment. Most are novel progesterone target genes. Real-time RT-PCR analysis of 55 genes showed a 100% confirmation rate. Twenty-six genes were regulated at both 3 and 24 hr. Studies using translation inhibitor suggest that most of the 26 genes are primary progesterone target genes. Progesterone consistently suppressed the expression of genes required for cell proliferation and metastasis and increased the expression of many tumor-suppressor genes. Progesterone also consistently decreased the expression of DNA repair and chromosome maintenance genes, which may be part of the mechanism leading to cell cycle arrest. These data suggest potential usefulness of progestin in combating ER-negative but PR-positive breast cancer and indicate that progesterone can exert a strong anticancer effect in hormone-independent breast cancer following PR reactivation. The identification of many novel progesterone target genes open up new avenues for in-depth elucidation of progesterone-mediated molecular networks. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15945099     DOI: 10.1002/ijc.21186

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

Review 1.  Progesterone receptors, their isoforms and progesterone regulated transcription.

Authors:  Britta M Jacobsen; Kathryn B Horwitz
Journal:  Mol Cell Endocrinol       Date:  2011-09-17       Impact factor: 4.102

Review 2.  Progesterone regulation of stem and progenitor cells in normal and malignant breast.

Authors:  Sunshine Daddario Axlund; Carol A Sartorius
Journal:  Mol Cell Endocrinol       Date:  2011-09-16       Impact factor: 4.102

3.  Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumors.

Authors:  Yiyang Li; Cheng Huang; Tamar Kavlashvili; Abby Fronk; Yuping Zhang; Yang Wei; Donghai Dai; Eric J Devor; Xiangbing Meng; Kristina W Thiel; Kimberly K Leslie; Shujie Yang
Journal:  Am J Cancer Res       Date:  2020-06-01       Impact factor: 6.166

4.  Lysine methylation of progesterone receptor at activation function 1 regulates both ligand-independent activity and ligand sensitivity of the receptor.

Authors:  Hwa Hwa Chung; Siu Kwan Sze; Amanda Rui En Woo; Yang Sun; Kae Hwan Sim; Xue Ming Dong; Valerie C-L Lin
Journal:  J Biol Chem       Date:  2014-01-10       Impact factor: 5.157

Review 5.  Role of nuclear progesterone receptor isoforms in uterine pathophysiology.

Authors:  Bansari Patel; Sonia Elguero; Suruchi Thakore; Wissam Dahoud; Mohamed Bedaiwy; Sam Mesiano
Journal:  Hum Reprod Update       Date:  2014-11-18       Impact factor: 15.610

6.  Uncovering New Drug Properties in Target-Based Drug-Drug Similarity Networks.

Authors:  Lucreţia Udrescu; Paul Bogdan; Aimée Chiş; Ioan Ovidiu Sîrbu; Alexandru Topîrceanu; Renata-Maria Văruţ; Mihai Udrescu
Journal:  Pharmaceutics       Date:  2020-09-16       Impact factor: 6.321

7.  A transcriptional network signature characterizes lung cancer subtypes.

Authors:  Hsun-Hsien Chang; Jonathan M Dreyfuss; Marco F Ramoni
Journal:  Cancer       Date:  2010-09-13       Impact factor: 6.860

Review 8.  The biology of progesterone receptor in the normal mammary gland and in breast cancer.

Authors:  Alison E Obr; Dean P Edwards
Journal:  Mol Cell Endocrinol       Date:  2011-12-13       Impact factor: 4.102

Review 9.  The role of the glutamine transporter ASCT2 in antineoplastic therapy.

Authors:  Estefânia Teixeira; Cláudia Silva; Fátima Martel
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-19       Impact factor: 3.333

Review 10.  Evolution, structure and emerging roles of C1ORF112 in DNA replication, DNA damage responses, and cancer.

Authors:  Jacob Edogbanya; Daniela Tejada-Martinez; Nigel J Jones; Amit Jaiswal; Sarah Bell; Rui Cordeiro; Sipko van Dam; Daniel J Rigden; João Pedro de Magalhães
Journal:  Cell Mol Life Sci       Date:  2021-02-24       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.